HRP20160392T1 - Cjepivo pcsk9 - Google Patents
Cjepivo pcsk9 Download PDFInfo
- Publication number
- HRP20160392T1 HRP20160392T1 HRP20160392TT HRP20160392T HRP20160392T1 HR P20160392 T1 HRP20160392 T1 HR P20160392T1 HR P20160392T T HRP20160392T T HR P20160392TT HR P20160392 T HRP20160392 T HR P20160392T HR P20160392 T1 HRP20160392 T1 HR P20160392T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- pcsk9
- fragments
- vaccine according
- amino acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 13
- 101150094724 PCSK9 gene Proteins 0.000 title 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 10
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (10)
1. Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 150 do 170 od PCSK9 u skladu sa
SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 205 do 225 od PCSK9 u skladu sa SEQ ID NO:9.
2. Cjepivo prema zahtjevu 1, naznačeno time, da su najmanje dva fragmenta odabrana iz skupine sastavljene od peptida koji imaju aminokiselinsku sekvencu SIPWNLERITPPR (SEQ ID NO:2), PEEDGTRFHRQASK (SEQ ID NO:3),
PEEDGTRFHRQA (SEQ ID NO:4), EEDGTRFHRQASK (SEQ ID NO:5),
EEDGTRFHRQAS (SEQ ID NO:6), SIPWNLERITP (SEQ ID NO:7) i
SIPWNLERIT (SEQ ID NO:8).
3. Cjepivo prema zahtjevu 1 ili 2, naznačeno time, da najmanje jedan fragment od PCSK9 ima aminokiselinsku sekvencu odabranu iz skupine koju čine SIPWNLERITPPR (SEQ ID NO:2), SIPWNLERITP (SEQ ID NO:7) i
SIPWNLERIT (SEQ ID NO:8), i najmanje jedan fragment od PCSK9 ima
aminokiselinsku sekvencu odabranu iz skupine koju čine PEEDGTRFHRQASK (SEQ ID NO:3), PEEDGTRFHRQA (SEQ ID NO:4), EEDGTRFHRQASK
(SEQ ID NO:5) i EEDGTRFHRQAS (SEQ ID NO:6).
4. Cjepivo prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da cjepivo obuhvaća SIPWNLERITPPR (SEQ ID NO:2) i PEEDGTRFHRQASK
(SEQ ID NO:3), SIPWNLERITPPR (SEQ ID NO:2) i
PEEDGTRFHRQA (SEQ ID NO:4), SIPWNLERITPPR (SEQ ID NO:2) i EEDGTRFHRQASK (SEQ ID NO:5), SIPWNLERITPPR (SEQ ID NO:2) i
EEDGTRFHRQAS (SEQ ID NO:6), PEEDGTRFHRQASK
(SEQ ID NO:3) i SIPWNLERITP (SEQ ID NO:7), PEEDGTRFHRQASK
(SEQ ID NO:3) i SIPWNLERIT (SEQ ID NO:8), PEEDGTRFHRQA
(SEQ ID NO:4) i SIPWNLERITP (SEQ ID NO:7), PEEDGTRFHRQA
(SEQ ID NO:4) i SIPWNLERIT (SEQ ID NO:8), EEDGTRFHRQASK
(SEQ ID NO:5) i SIPWNLERITP (SEQ ID NO:7), EEDGTRFHRQASK
(SEQ ID NO:5) i SIPWNLERIT (SEQ ID NO:8), EEDGTRFHRQAS
(SEQ ID NO:6) i SIPWNLERITP (SEQ ID NO:7), ili EEDGTRFHRQAS
(SEQ ID NO:6) i SIPWNLERIT (SEQ ID NO:8).
5. Cjepivo prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da najmanje dva fragmenta od PCSK9 sadrže cisteinski ostatak na C-završnom kraju i/ili na
N-završnom kraju.
6. Cjepivo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da su najmanje dva fragmenta od PCSK9 spojena na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
7. Cjepivo prema bilo kojem od zahtjeva 1 do 6, naznačeno time, da su najmanje dva fragmenta od PCSK9 formulirana za intradermalnu, subkutanu ili intramuskularnu primjenu.
8. Cjepivo prema bilo kojem od zahtjeva 1 do 7, naznačeno time, da cjepivo obuhvaća najmanje jedno pomoćno sredstvo, poželjno aluminijev hidroksid.
9. Cjepivo prema bilo kojem od zahtjeva 1 do 8, naznačeno time, da se upotrebljava u liječenju i/ili u prevenciji kardiovaskularnih bolesti, moždanog udara, perifernih vaskularnih bolesti, periferne arterijske okluzivne bolesti, koronarne srčane bolesti ili apoplektičkog cerebralnog insulta.
10. Cjepivo prema zahtjevu 9, naznačeno time, da se najmanje dva fragmenta od PCSK9 daju pojedincu za jednu dozu u količini od 0,1 ng do 10 mg, poželjno od 1 μg do 500 μg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181090.9A EP2570135B1 (en) | 2011-09-13 | 2011-09-13 | PCSK9 Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160392T1 true HRP20160392T1 (hr) | 2016-05-06 |
Family
ID=46851983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160392TT HRP20160392T1 (hr) | 2011-09-13 | 2016-04-15 | Cjepivo pcsk9 |
| HRP20170328TT HRP20170328T1 (hr) | 2011-09-13 | 2017-02-27 | Cjepivo pcsk9 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170328TT HRP20170328T1 (hr) | 2011-09-13 | 2017-02-27 | Cjepivo pcsk9 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9220762B2 (hr) |
| EP (2) | EP2570135B1 (hr) |
| JP (1) | JP6054400B2 (hr) |
| KR (1) | KR101983685B1 (hr) |
| CN (1) | CN103874504B (hr) |
| AU (1) | AU2012307348B8 (hr) |
| BR (1) | BR112014005756A2 (hr) |
| CA (1) | CA2848487A1 (hr) |
| CY (2) | CY1117335T1 (hr) |
| DK (2) | DK2570135T3 (hr) |
| ES (2) | ES2565757T3 (hr) |
| HR (2) | HRP20160392T1 (hr) |
| HU (2) | HUE028583T2 (hr) |
| IL (1) | IL231043A (hr) |
| LT (1) | LT2755678T (hr) |
| MX (1) | MX346883B (hr) |
| PL (2) | PL2570135T3 (hr) |
| PT (1) | PT2755678T (hr) |
| RS (1) | RS54639B1 (hr) |
| RU (2) | RU2640258C2 (hr) |
| SG (1) | SG11201400086QA (hr) |
| SI (2) | SI2570135T1 (hr) |
| SM (1) | SMT201600082B (hr) |
| WO (1) | WO2013037889A2 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| US10004791B2 (en) * | 2014-02-28 | 2018-06-26 | Affiris Ag | Peptide vaccines against PCSK9 |
| CN105085684B (zh) * | 2014-05-14 | 2020-04-17 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
| CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
| CA3058567A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
| CN107488215A (zh) * | 2017-07-19 | 2017-12-19 | 邱志华 | 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗 |
| WO2021154947A1 (en) * | 2020-01-28 | 2021-08-05 | Ubi Ip Holdings | Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders |
| KR20210158693A (ko) * | 2020-06-24 | 2021-12-31 | 바이오스트림테크놀러지스(주) | 항 ｐｃｓｋ９ 항체 및 이의 용도 |
| JPWO2022244845A1 (hr) * | 2021-05-19 | 2022-11-24 | ||
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5570806B2 (ja) * | 2006-05-11 | 2014-08-13 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｐｃｓｋ９遺伝子の発現を阻害するための組成物および方法 |
| AR066042A1 (es) * | 2007-04-13 | 2009-07-22 | Novartis Ag | Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9) |
| AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AT507604A1 (de) * | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | Behandlung von atherosklerose |
| PE20161560A1 (es) * | 2009-09-03 | 2017-01-11 | Pfizer Vaccines Llc | Vacuna de pcsk9 |
-
2011
- 2011-09-13 EP EP11181090.9A patent/EP2570135B1/en active Active
- 2011-09-13 SI SI201130773A patent/SI2570135T1/sl unknown
- 2011-09-13 ES ES11181090.9T patent/ES2565757T3/es active Active
- 2011-09-13 DK DK11181090.9T patent/DK2570135T3/en active
- 2011-09-13 HU HUE11181090A patent/HUE028583T2/en unknown
- 2011-09-13 RS RS20160183A patent/RS54639B1/en unknown
- 2011-09-13 PL PL11181090T patent/PL2570135T3/pl unknown
-
2012
- 2012-09-13 DK DK12759427.3T patent/DK2755678T3/en active
- 2012-09-13 US US14/344,879 patent/US9220762B2/en not_active Expired - Fee Related
- 2012-09-13 SG SG11201400086QA patent/SG11201400086QA/en unknown
- 2012-09-13 AU AU2012307348A patent/AU2012307348B8/en not_active Ceased
- 2012-09-13 SI SI201230903A patent/SI2755678T1/sl unknown
- 2012-09-13 ES ES12759427.3T patent/ES2618796T3/es active Active
- 2012-09-13 MX MX2014002879A patent/MX346883B/es active IP Right Grant
- 2012-09-13 RU RU2014114506A patent/RU2640258C2/ru not_active IP Right Cessation
- 2012-09-13 JP JP2014530217A patent/JP6054400B2/ja not_active Expired - Fee Related
- 2012-09-13 RU RU2017139094A patent/RU2017139094A/ru not_active Application Discontinuation
- 2012-09-13 CA CA2848487A patent/CA2848487A1/en not_active Abandoned
- 2012-09-13 EP EP12759427.3A patent/EP2755678B1/en active Active
- 2012-09-13 KR KR1020147009735A patent/KR101983685B1/ko active IP Right Grant
- 2012-09-13 HU HUE12759427A patent/HUE031860T2/en unknown
- 2012-09-13 CN CN201280044571.4A patent/CN103874504B/zh not_active Expired - Fee Related
- 2012-09-13 BR BR112014005756A patent/BR112014005756A2/pt not_active Application Discontinuation
- 2012-09-13 PT PT127594273T patent/PT2755678T/pt unknown
- 2012-09-13 LT LTEP12759427.3T patent/LT2755678T/lt unknown
- 2012-09-13 PL PL12759427T patent/PL2755678T3/pl unknown
- 2012-09-13 WO PCT/EP2012/067950 patent/WO2013037889A2/en active Application Filing
-
2014
- 2014-02-19 IL IL231043A patent/IL231043A/en active IP Right Grant
-
2015
- 2015-10-23 US US14/921,485 patent/US9669079B2/en not_active Expired - Fee Related
-
2016
- 2016-03-22 SM SM201600082T patent/SMT201600082B/xx unknown
- 2016-03-31 CY CY20161100266T patent/CY1117335T1/el unknown
- 2016-04-15 HR HRP20160392TT patent/HRP20160392T1/hr unknown
-
2017
- 2017-02-27 HR HRP20170328TT patent/HRP20170328T1/hr unknown
- 2017-03-16 CY CY20171100333T patent/CY1118856T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160392T1 (hr) | Cjepivo pcsk9 | |
| ES2656000T3 (es) | Anticuerpos frente a CGRP | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| HRP20171909T1 (hr) | Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| HRP20131229T1 (hr) | Lijeäśenje ateroskleroze | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| NI201100077A (es) | Terapia de combinación con epoxicetonas peptídicas. | |
| TWI455721B (zh) | 癌疫苗組合物 | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| ECSP045191A (es) | "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c" | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2010110564A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| EA201500061A1 (ru) | Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением | |
| NZ599839A (en) | Synergistic antiviral composition and use thereof | |
| JP2012102105A5 (hr) | ||
| JP2008531463A5 (hr) | ||
| NO20084053L (no) | Inhibering av tumorvekst | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| WO2015086686A3 (en) | Protease resistant peptides | |
| RU2012108179A (ru) | Новый пептид и его применение | |
| JP2014519514A5 (hr) | ||
| WO2006029487A8 (en) | Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis |